Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection A Feasibility Randomized Trial 英文参考文献.docVIP

下载本文档

2
0
约3.62万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection A Feasibility Randomized Trial 英文参考文献.doc

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection A Feasibility Randomized Trial 英文参考文献

AngiotensinConvertingEnzymeInhibitorandHMG-CoA ReductaseInhibitorasAdjunctTreatmentforPersons withHIVInfection:AFeasibilityRandomizedTrial JasonV.Baker1,2*,KathleenHupplerHullsiek3,RachelProsser1,DanielDuprez2,RichardGrimm1,2, RussellP.Tracy4,FrankRhame2,5,KeithHenry1,2,JamesD.Neaton3 1Department of Medicine, Hennepin County Medical Center (HCMC), Minneapolis, Minnesota, United States of America, 2Department of Medicine, University of Minnesota,Minneapolis,Minnesota,UnitedStatesofAmerica,3DepartmentofBiostatistics,UniversityofMinnesota,Minneapolis,Minnesota,UnitedStatesofAmerica, 4Department of Biochemistry, University of Vermont, Burlington, Vermont, United States of America, 5Department of Medicine, Abbott Northwestern Hospital, Minneapolis,Minnesota,UnitedStatesofAmerica Abstract Background: Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infectionreceivingeffectiveantiretroviraltherapy(ART)areneeded. Design and Methods: We conducted a 262 factorial feasibility study of lisinopril (L) (10mg daily) vs L-placebo in combinationwithpravastatin(P)(20mgdaily)vsP-placeboamongparticipantsreceivingARTwithundetectableHIVRNA levels,aFramingham10yearriskscore(FRS)$3%,andnoindicationforACE-Iorstatintherapy.Tolerabilityandadherence were evaluated. Longitudinal mixed models assessed changes in blood pressure (BP), blood lipids, and inflammatory biomarkersfrombaselinethroughmonths1and4. Results: Thirty-seven participants were randomized and 34 [lisinopril/pravastatin (n=9), lisinopril/P-placebo (n=8), L- placebo/pravastatin(n=9),L-placebo/P-placebo(n=8)]attendedatleastonefollow-upvisit.Participantswere97%male, 41%white,67%werecurrentsmokers,and65%weretakingaproteaseinhibitor.Medianagewas48years,CD4count483 cells/mm3,FRS7.79%,totalcholesterol184mg/dL,andLDL-C95mg/dL.Therewasnotreatmentdifferenceforpravastatin vsP-placebointotalcholesterol,LDL-C,oranyoftheinflammatorybiomarkers.Participantsrandomizedtolisinoprilvs.L- placeboha